"All that being said it would be far simpler just to directly answer BDAZ and GAC. In this situation as with some in the past where people are receiving exactly the same convoluted answer to a simple question, it makes me wonder if IR doesn’t fully understand what is being asked so asks management for and is given a vague catch all answer."

Good point Fouremm. In case anyone wants to try to ask the questions more clearly than I have, here is some company contact info:

Don McCaffrey <don@resverlogix.com>

Sarah Zapotichny <sarah@resverlogix.com>

Investor Relations <ir@resverlogix.com>

Michael Sweeney <msweeney@resverlogix.com>

clinicaltrials@resverlogix.com

info@resverlogix.com